Effect of Acipimox combined with Clopidogrel on the improvement of serum lipids and carotid atherosclerosis in hyperlipidemia rats
JIANG Aiwen1 DU Peishan2 WANG Shuzhen1 SHI Jinzheng1 LIU Yunning1 LI Fangjiang1
1.Department of Medicine, the First Affiliated Hospital of Hebei North University, Hebei Province, Zhangjiakou 075000, China;
2.Department of Cardiovascular Medicine, Zhangjiakou First Hospital, Hebei Province, Zhangjiakou 075000, China
Abstract：Objective To investigate the effect of the improvement of serum lipids and carotid atherosclerosis in hyperlipidemia rats by Acipimox combined with Clopidogrel in a hyperlipidemia rat model. Methods Ten rats from 45 rats were given normal feed as the normal group. The remaining 35 rats were given high-fat feed to model for 4 consecutive weeks, and 5 of them were randomly selected to judge whether the model was successful or not with increased total cholesterol (TC) level and statistically significant difference compared with the normal group. After successful modeling, the remaining 30 rats were randomly divided into the model group, the Acipimox group (32 mg/kg), and the combined group (32 mg/kg Acipimox + 10 mg/kg Clopidogrel ), with 10 rats in each group. The body weight, blood lipid index, hemorheology relevant parameters and serum inflammatory factors of the rats were measured. The carotid artery intimal thickness (IMT) and carotid artery media thickness (MT) were measured by small animal ultrasound. Results The levels of triglyceride (TG), TC and low-density lipoprotein cholesterol (LDL-C) in blood lipid of the Acipimox group were lower than those of the model group, while the levels of high-density lipoprotein cholesterol (HDL-C) were higher than those of the model group, and the differences were statistically significant (all P ＜ 0.05). There was no significant difference in body weight between the two groups (P ＞ 0.05). The levels of TG, TC, and LDL-C in serum lipids in the combined group were significantly lower than those in the model group, while the levels of TC and LDL-C in the combined group were lower than those in the Acipimox group, with statistically significant differences (all P ＜ 0.05). The whole blood viscosity, plasma viscosity and erythrocyte aggregation index in Acipimox group were significantly lower than those in model group, and the differences were statistically significant (all P ＜ 0.05). The whole blood viscosity, plasma viscosity and erythrocyte aggregation index in the combined group were significantly lower than those in the model group, and the whole blood viscosity index (shear rate 5 and 1), plasma viscosity and erythrocyte aggregation index in the combined group were significantly lower than those in the Acipimox group, with statistically significant differences (all P ＜ 0.05). Serum levels of tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6) in the Acipimox group were lower than those in the model group, while IL-10 were higher than those in the model group, and the differences were statistically significant (all P ＜ 0.05). The serum levels of TNF-α and IL-6 in the combined group were lower than those in the model group and the Acipimox group, and the level of IL-10 in the combined group was higher than that in the model group, and the differences were statistically significant (all P ＜ 0.05). IMT and MT in the model group, the Acipimox group and the combined group were all higher than those in the normal group, and the differences were statistically significant (P ＜ 0.05). IMT and MT in Acipimox group were lower than that in model group, and the differences were statistically significant (all P ＜ 0.05). MT in the combined group was significantly lower than that in the model group and the Acipimox group, and IMT was significantly lower than that in the model group, and the differences were statistically significant (all P ＜ 0.05). Conclusion Acipimox can effectively improve the hyperlipidemia and carotid atherosclerosis in rats induced by high-fat diet, and the protective effect is more significant when combined with Clopidogrel.
姜爱雯1 杜佩珊2 王淑珍1 石金铮1 刘云宁1 李方江1. 阿昔莫司联合氯吡格雷对高血脂大鼠血脂及颈动脉粥样硬化的改善作用[J]. 中国医药导报, 2020, 17(18): 19-23.
JIANG Aiwen1 DU Peishan2 WANG Shuzhen1 SHI Jinzheng1 LIU Yunning1 LI Fangjiang1. Effect of Acipimox combined with Clopidogrel on the improvement of serum lipids and carotid atherosclerosis in hyperlipidemia rats. 中国医药导报, 2020, 17(18): 19-23.
[1] Oikonomou E，Siasos G，Tousoulis D. Atherogenesis and hyperlipidemia a notstraightforward association：We really need a novel biomarker? [J]. Int J Cardiol，2016，202：586-588.
[2] Xi B，Liu F，Hao Y，et al. The growing burden of cardiovascular diseases in China[J]. Int J Cardiol，2014，174（3）：736-737.
[3] Kowalczyk E，Krzesiński P，Kura M，et al. Anthocyanins in medicine [J]. Pol J Pharmacol，2003，55（5）：699-702.
[4] 李思源，周杰，张鸥，等.冠状动脉钙化的影响因素[J].中华老年多器官疾病杂志，2018，17（3）：228-232.
[5] 安冬青，吴宗贵，梁春，等.血脂异常中西医结合诊疗专家共识[J].中国全科医学，2017，20（3）：262-269.
[6] 邓兰兰，潘玉华，冯金玉，等.颈动脉粥样硬化与血压及血脂的相关性分析[J].中国继续医学教育，2017，9（4）：129-131.
[7] Casanova F，Wood AR，Yaghootkar H，et al. A Mendelian Randomization Study Provides Evidence that Adiposity and Dyslipidemia Lead to Lower Urinary Albumin Creatinine Ratio，a Marker of Microvascular Function [J]. Diabetes，2020，69（5）：1072-1082.
[8] Vrablík M. Current and future trends in the treatment of dyslipidemias [J]. Vnitr Lek，2019，65（10）：643-650.
[9] Angoulvant D，Pathak A. Monoclonal antibodies in cardiovascular diseases and metabolic disorders today [J]. Med Sci （Paris），2019，35（12）：1014-1016.
[10] 汪杰.阿托伐他汀联合氯吡格雷对脑梗死患者hs-CRP MMP-9 TNF-α IMT及血脂的影响[J].中国实用神经疾病杂志，2016，19（1）：3-4.
[11] 宗晓芸，邓美珍.急性脑梗死患者颈动脉粥样硬化斑块经阿托伐他汀钙联合氢氯吡格雷治疗的临床观察[J].天津药学，2017，29（6）：44-45.
[12] 唐猛.内皮祖细胞与心血管缺血性疾病的研究进展[J].医药产业资讯，2006，11：126-128.
[13] 刘真成，边云飞，李嘉伟，等.血清尿酸与心血管疾病相关性的研究进展[J].中国医药导报，2019，16（29）：45-48.
[14] 黄汉烽.脑梗死患者血清尿酸水平与颈动脉粥样硬化斑块及脑梗死的关系研究[J].中国医药科学，2018，8（9）：194-196.
[15] El-Maksoud AAA，Korany RMS，El-Ghany IHA，et al. Dietary solutions to dyslipidemia：Milk protein-polysaccharide conjugates as liver biochemical enhancers [J]. J Food Biochem，2020，44（3）：e13142.
[16] Yu HH，Chen PC，Yang YH，et al. Statin reduces mortality and morbidity in systemic lupuserythematosus patients with hyperlipidemia： A nationwide population-based cohortstudy [J]. Atherosclerosis，2015，243（1）：11-18.
[17] Herrington W，Lacey B，Sherliker P，et al. Epidemiology of atherosclerosis and the potential to reduce the global burden of atherothrombotic disease [J]. Circ Res，2016， 118（4）：535-546.
[18] Colussi G，Catena C，Novello M，et al. Impact of omega-3 polyunsaturated fatty acids on vascular function and blood pressure： Relevance for cardiovascular outcomes [J]. Nutr Metab Cardiovasc Dis，2017，27（3）：191-200.
[19] 周晓丹，潘磊，王磊，等.门冬氨酸钾镁联合胺碘酮对慢性心力衰竭合并心律失常患者心功能、血液流变学和炎性因子的影响[J].疑难病杂志，2018，17（10）：1089-1093.
[20] Bhati P，Alam R，Moiz JA，et al. Subclinical inflammation and endothelial dysfunction are linked to cardiac autonomic neuropathy in type 2 diabetes [J]. J Diabetes Metab Disord，2019，18（2）：419-428.
[21] Ruiz LD，Zuelch ML，Dimitratos SM，et al. Adolescent Obesity：Diet Quality，Psychosocial Health，and Cardiometabolic Risk Factors [J]. Nutrients，2019，12（1）：43.
[22] Ehrenwald M，Wasserman A，Shenhar-Tsarfaty S，et al. Exercise capacity and body mass index - important predictors of change in resting heart rate [J]. BMC CardiovascDisord，2019，19（1）：307.
2020, Vol. 17 
京公网安备 11010502046598号